24 Nov 2010 16:44
For immediate release | 24 November 2010 |
3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
Director's Dealings
3D was informed today that James Noble, non-executive chairman of the Company, earlier purchased 200,000 ordinary shares in the Company at a price of 7.75p per share.
Following this transaction James Noble holds 10,333,760 ordinary shares representing 6.1% of the issued share capital of the Company.
For further information please contact:
3D Diagnostic Imaging Plc | |
Graham Lay, CEO | +44 (0) 1382 560 910 |
Oliver Cooke, FD | +44 (0) 20 7368 6959 |
finnCap | NOMAD & Broker |
Geoff Nash Henrik Persson | +44 (0)20 7600 1658 |
Buchanan Communications | Financial PR |
Diane Stewart Carrie Clement | +44 (0) 207 466 5000 |
Notes to Editors:
CarieScan PROtm
The PROtm is a highly accurate, easy to use, hand held device for the early detection and monitoring of dental caries (tooth decay). The PROtm already has CE Mark and FDA 510K approval for sale in Europe and the USA.
The CarieScan PROtm measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.
The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost. The CarieScan PROtm consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PROtm.